Dr. Elliot Landaw's research interests center on kinetic analysis, compartmental modeling, nonlinear estimation and optimization problems in pharmacokinetics, physiology and molecular biology. His methodological interests in parameter estimation, optimal/robust sampling designs and adaptive control for computational models address problems arising from a variety of collaborations with experimental and clinical groups. Applied projects include the optimal design of DNA-sequence reading molecules, the use of model-based adaptive control for cancer chemotherapy and modeling glucose transport across the blood-brain barrier.
Selected Cancer-Related Publications:
Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, Komisopoulou E, Brown LM, Loo JA, Landaw EM, Sawyers CL, Graeber TG. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci U S A. 2006; 103:19466-71.
Kim G, Rajasekaran SA, Thomas G, Rosen EA, Landaw EM, Shintaku P, Lassman C, Said J, Rajasekaran AK. Renal clear-cell carcinoma: an ultrastructural study on the junctional complexes. Histol Histopathol. 2005; 20:35-44.
Shankar DB, Cheng JC, Kinjo K, Federman N, Moore TB, Gill A, Rao NP, Landaw EM, Sakamoto KM. The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. Cancer Cell. 2005; 7:351-62.
Crans-Vargas HN, Landaw EM, Bhatia S, Sandusky G, Moore TB, Sakamoto KM. Expression of cyclic adenosine monophosphate response-element binding protein in acute leukemia. Blood. 2002; 99:2617-2619.
Lopez AM, Pegram MD, Slamon DJ, Landaw EM. A model-based approach for assessing in vivo combination therapy interactions. Proc Natl Acad Sci U S A. 1999; 96:13023-13028.